Spero Therapeutics (SPRO) EPS (Weighted Average and Diluted) (2021 - 2026)
Spero Therapeutics posted quarterly EPS (Weighted Average and Diluted) of -$0.13 for Q1 2026, up 48.0% year-on-year from -$0.09 in Q1 2025, and down 123.21% on a QoQ basis from $0.56 in Q4 2025.
Spero Therapeutics (SPRO) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.13 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 48.0% year-over-year to -$0.13; the trailing twelve-month figure through Mar 2026 stood at $0.27 (up 121.09% YoY), and the FY2025 full-year result was $0.15, up 111.81% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.13, down from $0.56 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.97 in Q4 2023 and bottomed at -$1.01 in Q1 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.24 (2024), against an average of -$0.12.
- The widest annual swing landed in 2024, when EPS (Weighted Average and Diluted) plunged 433.33%; it then jumped 247.37% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.93 in 2022, then advanced by 4.3% to $0.97 in 2023, then sank by 139.18% to -$0.38 in 2024, then surged by 247.37% to $0.56 in 2025, then plunged by 123.21% to -$0.13 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.13 (Q1 2026), $0.56 (Q4 2025), and -$0.13 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | -0.13 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.13 |
| Dec 31, 2025 | 0.56 |
| Sep 30, 2025 | -0.13 |
| Jun 30, 2025 | -0.03 |
| Mar 31, 2025 | -0.25 |
| Dec 31, 2024 | -0.38 |
| Sep 30, 2024 | -0.32 |
| Jun 30, 2024 | -0.33 |
| Mar 31, 2024 | -0.24 |
| Dec 31, 2023 | 0.97 |
| Sep 30, 2023 | -0.06 |
| Jun 30, 2023 | -0.23 |
| Mar 31, 2023 | -0.25 |
| Dec 31, 2022 | 0.93 |
| Sep 30, 2022 | -0.33 |
| Jun 30, 2022 | -0.87 |
| Mar 31, 2022 | -1.01 |
| Dec 31, 2021 | -0.92 |
| Sep 30, 2021 | -0.70 |
| Jun 30, 2021 | -0.63 |